Skip to main content
Clinical Trials/NCT02224443
NCT02224443
Unknown
Phase 4

Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients-A Single Center,Randomized, Double-blinded,Controlled Study

First Affiliated Hospital Xi'an Jiaotong University0 sites90 target enrollmentSeptember 2014

Overview

Phase
Phase 4
Intervention
dexmedetomidine
Conditions
Postoperative Cognitive Dysfunction
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Enrollment
90
Primary Endpoint
Change from baseline to postoperation in cognitive function
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to identify the effects of different doses of dexmedetomidine on postoperative cognitive dysfunction in elderly hypertensive patients

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
September 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ma Zhengmin

Anaesthetist

First Affiliated Hospital Xi'an Jiaotong University

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • Elective gastrointestinal surgery
  • American Society of Anesthesiologists class II to III
  • Aged between 65 and 80 years old
  • Weight between 45 and 75 kilogram,Body Mass Index between 19 and 24 kg.m-2
  • With primary hypertension reaching or more than 1 year
  • Normal cognitive function,mini-mental state examination more than 27

Exclusion Criteria

  • Severe arrhythmia,atrioventricular block and secondary hypertension
  • Liver and kidney dysfunction,pulmonary disease,endocrine disease
  • Suspected or confirmed difficult airway
  • Any disease or pathologic change will interfere study result
  • Inability to exchange with serious visual and hearing impairment
  • Long term use of sedative-hypnotic drugs and antidepressant drug
  • Addicted to alcohol, tobacco or drug
  • Neuromuscular disease
  • Suspected of malignant hyperthermia
  • Allergic to investigational products or with other contraindication

Arms & Interventions

Group A, dexmedetomidine , 0.3µg.kg-1.h-1

Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation

Intervention: dexmedetomidine

Group A, dexmedetomidine , 0.3µg.kg-1.h-1

Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation

Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate

Group A, dexmedetomidine , 0.3µg.kg-1.h-1

Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation

Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane

Group B,dexmedetomidine , 0.5µg.kg-1.h-1

Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation

Intervention: dexmedetomidine

Group B,dexmedetomidine , 0.5µg.kg-1.h-1

Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation

Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate

Group B,dexmedetomidine , 0.5µg.kg-1.h-1

Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation

Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane

Group C ,normal saline

Normal saline infusion will be given with the same infusion volume as group A and B

Intervention: normal saline

Group C ,normal saline

Normal saline infusion will be given with the same infusion volume as group A and B

Intervention: midazolam,fentanyl,etomidate,Cisatracurium besylate

Group C ,normal saline

Normal saline infusion will be given with the same infusion volume as group A and B

Intervention: cisatracurium besylate,propofol,remifentanil,sevoflurane

Outcomes

Primary Outcomes

Change from baseline to postoperation in cognitive function

Time Frame: One day before operation,third day after operation,sixth day after operaion

Mini-mental State Examination

Change from baseline to postoperation in recent memory

Time Frame: One day before operation,third day after operation,sixth day after operation

Rey Auditory Verbal Learning Test

Change from baseline to postoperation in depression scale

Time Frame: One day before operation,third day after operation,sixth day after operation

Beck Depression Inventory

Change from baseline to postoperation in visual space and directional force

Time Frame: One day before operation,third day after operation,sixth day after operaion

Trail Making Test A,Trail Making Test B

Change from baseline to postoperation in attention

Time Frame: One day before operation,third day after operation,sixth day after operaion

Digit Span Test

Change from baseline to postoperation in pain scores

Time Frame: One day before operation,third day after operation,sixth day after operation

Visual analog scales

Secondary Outcomes

  • The urine volume during operation(From begining of cutting skin to the end of skin closure,an expected average of 3 hours)
  • The duration of operation(From begining of cutting skin to the end of skin closure,an expected average of 3 hours)
  • The blood volume during the operation(From begining of cutting skin to the end of skin closure,an expected average of 3 hours)
  • The dose of drugs used during operation(From begining of cutting skin to the end of skin closure,an expected average of 3 hours)

Similar Trials